Search the Newsreel

Proto Labs Inc (PRLB) Stock News Today

This page provides the latest news, earnings, analyst ratings, and key developments for Proto Labs Inc (PRLB) stock. It highlights a recent earnings report from Q2 2026, where Protolabs announced record revenue driving margin expansion. The page also displays current stock performance data and …

Protagonist Therapeutics (PTGX): State Street discloses 5.2% beneficial ownership stake

State Street Corporation has reported a 5.2% passive beneficial ownership stake in Protagonist Therapeutics, Inc., holding 3,321,554 common shares. The filing indicates that State Street exercises shared voting power over 3,157,671 shares and shared dispositive power over all 3,321,554 shares through various investment management …

Intelligent Protection Management Corp (IPM) Stock News Today

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) is showing significant upside potential due to notable revisions in its earnings estimates, reflecting growing optimism from analysts. The company's earnings outlook continues to improve, with current-quarter EPS expected to increase by 446.8% and full-year EPS by 280.0%. This positive trend …

Tianjin Capital Signs Connected EPC Deal for Reclaimed Water Projects

Sprott Inc. Is Maintained at Hold by TD

TD Securities has reiterated its "Hold" rating on Sprott Inc., a prominent investment company specializing in precious metals and real asset investments. This indicates a neutral outlook on the company's stock performance.

HC Wainwright Has Negative Forecast for PTGX Q3 Earnings

Prothena publishes corporate overview presentation on protein-dysregulation drug pipeline

Prothena has released a corporate overview detailing its protein-dysregulation drug pipeline, highlighting partnered late-stage programs such as Roche’s prasinezumab for Parkinson’s disease and Novo Nordisk’s coramitug for ATTR cardiomyopathy, both with primary completion expected in 2029. The company also noted a potential $55 million …

Protagonist Therapeutics (PTGX) Stock Price Surges After Profit Inflection

Protagonist Therapeutics (PTGX) saw its stock price surge after reporting a significant profit inflection in Q2 2026, with revenue reaching US$213.5 million and basic EPS at US$2.47, a major turnaround from previous losses. This shift is largely attributed to the strong performance of ICOTYDE …

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System

The California State Teachers Retirement System increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 22.2% in Q1, now holding 58,677 shares valued at $6.2 million. Despite insider sales totaling $11.5 million in the last 90 days, institutional investors own 98.63% of the company, and …

Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside

Protagonist Therapeutics, Inc. (PTGX) has seen its average 12-month price target raised to $152.14 by 14 analysts, up from $148.93. This updated target suggests an 11% potential upside from the August 5 closing price. The consensus rating for PTGX remains "Buy," with 13 analysts …

Prothena: Q2 Earnings Snapshot

Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone

Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M

Protagonist Therapeutics, Inc. (PTGX) announced its Q2 revenue of $213.5 million, surpassing the FactSet estimate of $199.8 million. This report highlights a stronger-than-expected financial performance for the quarter.

Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst …

Protagonist Therapeutics stock hits all-time high at 143.43 USD

Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite …

PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00

Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) reported a narrower-than-expected Q2 loss of $0.32 per share, beating the Zacks Consensus Estimate of a $0.39 loss. However, the company missed revenue estimates, posting $1.01 million against an expected $1.94 million, continuing a trend of missing revenue forecasts. Despite the earnings …

PTGX Maintained by Barclays -- Price Target Raised to $153

Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider …

Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026.

Prothena Corporation plc has provided an update on its equity buyback plan, initially announced on February 27, 2026. Between April 1, 2026, and June 30, 2026, the company repurchased 1,454,898 shares for $14.98 million, representing 2.74% of its shares. This brings the total repurchased …

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings

FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4%

FMR LLC has disclosed a significant 13.8% beneficial ownership stake in Prothena Corporation plc (PRTA), holding 7,199,218 shares as of June 30, 2026. Abigail P. Johnson is noted with sole dispositive power over these shares, and the filing highlights that Fidelity Growth Company Commingled …

Why Did Sprott Inc. (TSX:SII) Stock Surge 9.90% on 5 August 2026?

Protagonist Therapeutics earnings beat by $0.16, revenue topped estimates

Sprott Inc. (NYSE: SII) doubles adjusted EBITDA as gold pulls back

Sprott Inc. reported significantly increased profitability in Q2 2026, with net income rising to $34.3 million and Adjusted EBITDA more than doubling to $50.8 million, despite a 15% decline in Assets Under Management (AUM) due to a pullback in precious metals prices. The company's …

Sprott Inc. (SII.TO) Stock Price, News, Quote & History

Sprott Inc. (SII.TO) closed at 157.55 CAD on August 6, 2026, down 2.69%, with a market capitalization of 4.054 billion CAD. The company, an asset management firm based in Toronto, Canada, has shown strong performance with a 1-year return of 71.80% and a 5-year …

TD Issues Positive Forecast for Sprott (TSE:SII) Stock Price

Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Sprott (TSX:SII) Stock Profit Surge Meets AUM Pullback Risk

SPROTT INC : CANACCORD GENUITY CUTS TARGET PRICE TO C$183 FROM C$230

Canaccord Genuity has reduced its target price for Sprott Inc. (SII.TO) to C$183 from C$230. The updated target price reflects an analyst's revised valuation for the company. This information was reported by Reuters.

PROTAGONIST THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $175 FROM $130

Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.

Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary

Protagonist Therapeutics, Inc reported significantly increased revenue of $213.48M and diluted EPS of $2.29 for the 2026 quarter, largely due to license and collaboration revenue from a Takeda opt-out payment and a J&J milestone. The company achieved a net income of $162.85M compared to …

Responsive Playbooks and the SII Inflection

This article provides an in-depth analysis of Sprott Inc. (NYSE: SII), highlighting strong near-term sentiment potentially influencing mid-term neutrality and long-term positive bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis …

Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Protagonist Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is available on TradingView, sourced from Refinitiv and Reuters.

Protagonist Therapeutics (NASDAQ: PTGX) jumps on $269.8M 2026 collaboration revenue

Joseph B. Hayek and Suresh Krishna Join Apogee Enterprises’ Board of Directors

MINNEAPOLIS, August 05, 2026--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, announced today that its Board of Directors has elected Joseph B. Hayek, President and …